Cryo-Cell International (CCEL) Co-CEO reports 75,000 new stock options and updated holdings
Rhea-AI Filing Summary
Cryo-Cell International Co-CEO Mark Portnoy reported new stock option grants and updated his holdings in company securities. On January 7, 2026, he was granted a stock option for 50,000 shares of common stock at an exercise price of $3.89 per share, expiring on January 7, 2031. This grant, made under the Cryo-Cell 2022 Stock Incentive Plan, is split into three equal tranches that each require both time-based vesting and stock price hurdles of $6, $8, and $10 per share over 20 consecutive trading days.
Portnoy also received a separate stock option for 25,000 shares at an exercise price of $3.89 per share, expiring January 7, 2031, which vests one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028. Following these grants, he reports 821,973 common shares held directly, 42,266 shares held indirectly via a 401(k), and 71,529 shares held indirectly by Capital Asset Fund #1 Limited Partnership, where he may be deemed a beneficial owner as general partner.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 50,000 | $3.89 | $195K |
| Grant/Award | Stock Option | 25,000 | $3.89 | $97K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Shares of common stock held by Capital Asset Fund #1 Limited Partnership, as to which Mark Portnoy may be deemed beneficial owner as its general partner. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027. The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company. Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.
FAQ
What insider activity did Cryo-Cell International (CCEL) report for Mark Portnoy?
The report shows that Mark Portnoy, a director, Co-CEO and 10% owner of Cryo-Cell International, received new stock option grants on January 7, 2026 and updated his direct and indirect holdings of the company’s common stock and options.
How many new stock options did Mark Portnoy receive and at what exercise price?
On January 7, 2026, Portnoy was granted two sets of stock options: one for 50,000 shares and another for 25,000 shares, each with an exercise price of $3.89 per share and an expiration date of January 7, 2031.
How do the 25,000 new stock options granted to Mark Portnoy vest?
The separate 25,000-share stock option grant at an exercise price of $3.89 per share vests one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028, assuming continued service.
What existing stock options does Mark Portnoy hold in Cryo-Cell International?
Portnoy holds multiple existing stock option positions, including options on 22,222, 20,000, 100,000, 25,000, 25,000, and 25,000 shares with exercise prices ranging from $4.30 to $12.27 per share and expiration dates between 2019 and 2030, each with specified vesting schedules.